Efficacy of Pramipexole for Treatment of Apathy in Parkinson’s Disease


Background: Apathy occurs frequently in patients with Parkinson’s disease (PD), and has a negative impact on activities of daily living through loss of motivation. Pramipexole (PPX), which shows preferential affinity for D3 dopamine receptor in the mesolimbic system, is thought to influence mood and motivation. Therefore, we conducted an open-label case-control study to examine the effect of PPX on apathy in PD. Methods: We studied 36 PD patients (mean age, 70.4 ± 8.1 years), who had been treated only with L-DOPA. PPX was added to L-DOPA treatment in 24 patients (PPX group) and other 12 patients continued with L-DOPA alone (non-PPX group). The study period was 8 weeks. Apathy was assessed using the revised apathy scale for Japanese. Motor function was assessed with part III of the Unified Parkinson’s Disease Rating Scale (UPDRS). Results: Seventeen of 36 patients (47%) were diagnosed as having apathy. In the PPX group, apathy scale significantly improved from 17.3 to 13.8 at week 8 (p < 0.05). Motor function also improved significantly from 16.1 to 7.6 at week 8 (p < 0.0001). In the non-PPX group, apathy scale and UPDRS both showed no change during the study period. There was no correlation between changes in apathy scale and UPDRS in either the PPX or non-PPX group. Conclusion: PPX may be effective for treating apathy as well as motor dysfunction in PD.

Share and Cite:

Oguro, H. , Kadota, K. , Ishihara, M. , Okada, K. and Yamaguchi, S. (2014) Efficacy of Pramipexole for Treatment of Apathy in Parkinson’s Disease. International Journal of Clinical Medicine, 5, 885-889. doi: 10.4236/ijcm.2014.515118.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Piercey, M.F., Hoffmann, W.E., Smith, M.W. and Hyslop, D.K. (1996) Inhibition of Dopamine Neuron Firing by Pramipexole, a Dopamine D3 Receptor-Preferring Agonist: Comparison to Other Dopamine Receptor Agonists. European Journal of Pharmacology, 312, 35-44.
[2] Marin, R.S. (1991) Apathy: A Neuropsychiatric Syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences, 3, 243-254.
[3] Martínez-Horta, S., Riba, J., de Bobadilla, R.F., Pagonabarraga, J., Pascual-Sedano, B., Antonijoan, R.M., et al. (2014) Apathy in Parkinson’s Disease: Neurophysiological Evidence of Impaired Incentive Processing. The Journal of Neuroscience, 34, 5918-5926.
[4] Pedersen, K.F., Larsen, J.P., Alves, G. and Aarsland, D. (2009) Prevalence and Clinical Correlates of Apathy in Parkinson’s Disease: A Community-Based Study. Parkinsonism & Related Disorders, 15, 295-299.
[5] Thobois, S., Lhommée, E., Klinger, H., Ardouin, C., Schmitt, E., Bichon, A., et al. (2013) Parkinsonian Apathy Responds to Dopaminergic Stimulation of D2/D3 Receptors with Piribedil. Brain, 136, 1568-1577.
[6] Okada, K., Kobayashi, S., Yamagata, S., Takahashi, K. and Yamaguchi, S. (1997) Poststroke Apathy and Regional Cerebral Blood Flow. Stroke, 28, 2437-2441.
[7] Möller, J.C., Oertel, W.H., Köster, J., Pezzoli, G. and Provinciali, L. (2005) Long-Term Efficacy and Safety of Pramipexole in Advanced Parkinson’s Disease: Results from a European Multicenter Trial. Movement Disorders, 20, 602-610.
[8] Lemke, M.R., Brecht, H.M., Koester, J. and Reichmann, H. (2006) Effects of the Dopamine Agonist Pramipexole on Depression, Anhedonia and Motor Functioning in Parkinson’s Disease. Journal of the Neurological Sciences, 248, 266-270.
[9] Leentjens, A.F., Koester, J., Fruh, B., Shephard, D., Barone, P. and Houben, J.J. (2009) The Effect of Pramipexole on Mood and Motivational Symptoms in Parkinson’s Disease: A Meta-Analysis of Placebo-Controlled Studies. Clinical Therapeutics, 31, 89-98.
[10] Kohno, N., Abe, S., Toyoda, G., Oguro, H., Bokura, H. and Yamaguchi, S. (2010) Successful Treatment of Post-Stroke Apathy by the Dopamine Receptor Agonist Ropinirole. Journal of Clinical Neuroscience, 17, 804-806.
[11] Onoda, K., Kuroda, Y., Yamamoto, Y., Abe, S., Oguro, H., Nagai, A., et al. (2011) Post-Stroke Apathy and Hypoperfusion in Basal Ganglia: SPECT Study. Cerebrovascular Diseases, 31, 6-11.
[12] Guttman, M. and Jaskolka, J. (2001) The Use of Pramipexole in Parkinson’s Disease: Are Its Actions D3 Mediated? Parkinsonism & Related Disorders, 7, 231-234.
[13] Corrigan, M.H., Denahan, A.Q., Wright, C.E., Ragual, R.J. and Evans, D.L. (2000) Comparison of Pramipexole, Fluoxetine, and Placebo in Patients with Major Depression. Depress Anxiety, 11, 58-65.
[14] Remy, P., Doder, M., Lees, A., Turjanski, N. and Brooks, D. (2005) Depression in Parkinson’s Disease: Loss of Dopamine and Noradrenaline Innervation in the Limbic System. Brain, 128, 1314-1322.
[15] Hori, H. and Kunugi, H. (2012) The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial. The Scientific World Journal, 2012, Article ID: 372474.
[16] Bower, P., Kontopantelis, E., Sutton, A., Kendrick, T., Richards, D.A., Gilbody, S., et al. (2013) Influence of Initial Severity of Depression on Effectiveness of Low Intensity Interventions: Meta-Analysis of Individual Patient Data. BMJ, 346, f540.
[17] Parkinson Study Group (2000) Pramipexole vs. Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial. The Journal of the American Medical Association, 284, 1931-1938.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.